Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial

Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
doi: https://doi.org/10.1101/2021.01.05.21249237

Article Information

doi 
https://doi.org/10.1101/2021.01.05.21249237
History 
  • January 12, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Olha Holubovska1,11,
  2. Denisa Bojkova2,11,
  3. Stefano Elli3,11,
  4. Marco Bechtel2,
  5. David Boltz4,
  6. Miguel Muzzio4,
  7. Xinjian Peng4,
  8. Frederico Sala3,
  9. Cesare Cosentino3,
  10. Alla Mironenko5,
  11. Jens Milde6,
  12. Yuriy Lebed7,
  13. Holger Stammer6,
  14. Andrew Goy8,
  15. Marco Guerrini3,
  16. Lutz Mueller9,*,
  17. Jindrich Cinatl2,*,
  18. Victor Margitich8,* and
  19. Aartjan J. W. te Velthuis10,11,*
  1. 1O.O. Bogomolets National Medical University, T. Shevchenko blvd., 13, Kyiv, Ukraine
  2. 2Institute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
  3. 3Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”, Via Giuseppe Colombo 81, 20133 Milano, Italy
  4. 4IIT Research institute, 10 W 35th St, Chicago, IL 60616, United States
  5. 5L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Department of respiratory and other viral infections, Amosova str 5a, 03083, Kyiv, Ukraine
  6. 6Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany
  7. 7Pharmaxi LLC, Filatova Str., 10A, office 3/20, 01042, Kyiv, Ukraine
  8. 8Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine
  9. 9Dr. Regenold GmbH, Zöllinplatz 4, D-79410 Badenweiler, Germany
  10. 10Division of Virology, Department of Pathology, Addenbrooke’s Hospital, University of Cambridge, Hills Road, CB2 2QQ, United Kingdom
  1. ↵*Corresponding authors. E-mail: ajwt6{at}cam.ac.uk, cinatl{at}em.uni-frankfurt.de, lutz.mueller{at}regenold.com, v.margitich{at}farmak.ua

  1. ↵11 These authors contributed equally

Back to top
Posted January 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
medRxiv 2021.01.05.21249237; doi: https://doi.org/10.1101/2021.01.05.21249237
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area